spacer
home > ebr > autumn 2021 > the route to sustainable procurement
PUBLICATIONS
European Biopharmaceutical Review

The Route to Sustainable Procurement

Sustainability and environmental protection efforts are now mainstream in society, and have become a common goal across all major industries: the biopharma industry is by no means an exception. A recent paper by Biogen lists the following drivers for biopharma to improve its environmental practices fast: increased life expectancies and chronic disease rates, the increasing representation of eco-conscious millennials in the workforce, a more stringent regulatory environment, climate change, and changing investor expectations (1).

The biopharma industry has been working on the issue for quite some time, and as a recent survey by Pelican Biothermal confirms, 66% of key opinion leaders in the biopharma cold chain always factor sustainability into cold chain purchasing decisions (2). In addition to this, 64% of organisations report that they always inquire about sustainability when performing audits of suppliers, and 52% indicated that they, in turn, were audited for sustainability by vendors supplying their organisations, highlighting that the biopharma industry is rapidly moving towards prioritisation of sustainability.

Within these purchasing decisions, the sustainability of medical devices is equally important. Increase in self-administration with biologics and the need to create combination products for subcutaneous delivery mean that pharmaceutical businesses must select appropriate delivery devices for their drugs; these devices are likely to be single use only.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
George I’ons is currently Head of Product Strategy and Insights at Owen Mumford having worked for the original equipment manufacturer and now Pharmaceutical Services division of the organisation since 2006. His current focus is on deciphering the rapidly changing pharma and biotech sectors in relation to their needs for combination products. In his previous roles in business development he worked closely alongside R&D to develop devices for a variety of global pharma and diagnostic clients. Prior to Owen Mumford, George worked for Abbott in EMEA marketing roles in Germany, focusing on their diabetes business.
spacer
George I’ons
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

SGS QUAY PHARMA RECEIVES QUEEN’S AWARD FOR INDUSTRY

Leading pharmaceutical contract development and manufacturing organisation (CDMO) SGS Quay Pharma has received its Queen’s Award for Enterprise. The award was presented by the Lord Lieutenant of Clwyd, Henry Fetherstonhaugh, OBE, in a special ceremony at the company’s global headquarters in Deeside Industrial Park, Flintshire.
More info >>

White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement